Back to Search
Start Over
Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting
- Source :
- Blood Advances. 3:1027-1032
- Publication Year :
- 2019
- Publisher :
- American Society of Hematology, 2019.
-
Abstract
- Key Points Teriflunomide, the active metabolite of leflunomide, downregulates c-Myc expression through inhibition of PIM kinases. Leflunomide together with lenalidomide significantly extended survival in an in vivo MM model.
- Subjects :
- Drug synergism
Proto-Oncogene Proteins c-myc
Mice
chemistry.chemical_compound
Proto-Oncogene Proteins c-pim-1
In vivo
hemic and lymphatic diseases
Teriflunomide
Tumor Cells, Cultured
medicine
Animals
Humans
Enzyme Inhibitors
Lenalidomide
Active metabolite
Leflunomide
Drug Synergism
Hematology
Stimulus Report
chemistry
Pim kinases
Cancer research
Drug Therapy, Combination
Multiple Myeloma
Combination method
medicine.drug
Subjects
Details
- ISSN :
- 24739537 and 24739529
- Volume :
- 3
- Database :
- OpenAIRE
- Journal :
- Blood Advances
- Accession number :
- edsair.doi.dedup.....4d8baa13a1c126dc88b70a6953690f13